Janus kinase (JAK) inhibitors effectively stimulate hair growth, compared with placebo, for patients with alopecia areata, according to a new systematic review and meta-analysis. Oral JAK inhibitors are more effective than topical formulations.
In an analysis of seven trials that included almost 2000 patients, the odds of achieving 50% improvement were more than five times greater for patients who received JAK inhibitors, compared with patients who received placebo.
"Although the safety and tolerability of JAK inhibitors were acceptable, longer randomized controlled trials are needed to further assess the effectiveness and safety of these treatments for alopecia areata," write study author Ming Liu, PhD, of McMaster University in Hamilton, Ontario, Canada, and colleagues.
The findings were published June 27 in JAMA Network Open.